146 related articles for article (PubMed ID: 2777072)
1. The distribution of debrisoquine metabolic phenotypes and implications for the suggested association with lung cancer risk.
Caporaso N; Pickle LW; Bale S; Ayesh R; Hetzel M; Idle J
Genet Epidemiol; 1989; 6(4):517-24. PubMed ID: 2777072
[TBL] [Abstract][Full Text] [Related]
2. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.
Roots I; Drakoulis N; Ploch M; Heinemeyer G; Loddenkemper R; Minks T; Nitz M; Otte F; Koch M
Klin Wochenschr; 1988; 66 Suppl 11():87-97. PubMed ID: 2846954
[TBL] [Abstract][Full Text] [Related]
3. Lung cancer risk, occupational exposure, and the debrisoquine metabolic phenotype.
Caporaso N; Hayes RB; Dosemeci M; Hoover R; Ayesh R; Hetzel M; Idle J
Cancer Res; 1989 Jul; 49(13):3675-9. PubMed ID: 2731181
[TBL] [Abstract][Full Text] [Related]
4. Genetic predisposition to Balkan endemic nephropathy: ability to hydroxylate debrisoquine as a host risk factor.
Nikolov IG; Chernozemsky IN; Idle JR
IARC Sci Publ; 1991; (115):289-96. PubMed ID: 1820343
[TBL] [Abstract][Full Text] [Related]
5. Lung tumor resection does not affect debrisoquine metabolism.
Shaw GL; Falk RT; Deslauriers J; Nesbitt JC; McKneally MF; Frame JN; Feld R; Issaq HJ; Ruckdeschel JC; Hoover RN
Cancer Epidemiol Biomarkers Prev; 1994 Mar; 3(2):141-4. PubMed ID: 8049635
[TBL] [Abstract][Full Text] [Related]
6. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
Kallio J; Lindberg R; Huupponen R; Iisalo E
Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
[TBL] [Abstract][Full Text] [Related]
7. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
Du YL; Lou YQ
Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
[TBL] [Abstract][Full Text] [Related]
8. [Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].
Dick B; Küpfer A; Molnàr J; Braunschweig S; Preisig R
Schweiz Med Wochenschr; 1982 Jul; 112(30):1061-7. PubMed ID: 7123181
[TBL] [Abstract][Full Text] [Related]
9. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
Sommers DK; Moncrieff J; Avenant J
Hum Toxicol; 1988 May; 7(3):273-6. PubMed ID: 3391625
[TBL] [Abstract][Full Text] [Related]
10. Interstrain comparison of hepatic and renal microsomal carcinogen metabolism and liver S9-mediated mutagenicity in DA and Lewis rats phenotyped as poor and extensive metabolizers of debrisoquine.
Hietanen E; Malaveille C; Camus AM; Béréziat JC; Brun G; Castegnaro M; Michelon J; Idle JR; Bartsch H
Drug Metab Dispos; 1986; 14(1):118-26. PubMed ID: 2868854
[TBL] [Abstract][Full Text] [Related]
11. Debrisoquine oxidation phenotype and susceptibility to lung cancer.
Speirs CJ; Murray S; Davies DS; Biola Mabadeje AF; Boobis AR
Br J Clin Pharmacol; 1990 Jan; 29(1):101-9. PubMed ID: 2153391
[TBL] [Abstract][Full Text] [Related]
12. Lung cancer and the debrisoquine metabolic phenotype.
Caporaso NE; Tucker MA; Hoover RN; Hayes RB; Pickle LW; Issaq HJ; Muschik GM; Green-Gallo L; Buivys D; Aisner S
J Natl Cancer Inst; 1990 Aug; 82(15):1264-72. PubMed ID: 2374176
[TBL] [Abstract][Full Text] [Related]
13. The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.
Caporaso NE; Shields PG; Landi MT; Shaw GL; Tucker MA; Hoover R; Sugimura H; Weston A; Harris CC
Environ Health Perspect; 1992 Nov; 98():101-5. PubMed ID: 1362537
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
15. The metabolism of [14C]-debrisoquine in man.
Idle JR; Mahgoub A; Angelo MM; Dring LG; Lancaster R; Smith RL
Br J Clin Pharmacol; 1979 Mar; 7(3):257-66. PubMed ID: 371651
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of neuroleptics on debrisoquine oxidation in man.
Syvälahti EK; Lindberg R; Kallio J; De Vocht M
Br J Clin Pharmacol; 1986 Jul; 22(1):89-92. PubMed ID: 2874826
[TBL] [Abstract][Full Text] [Related]
17. Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology.
Pollock BG; Perel JM; Altieri LP; Kirshner M; Fasiczka AL; Houck PR; Reynolds CF
Psychopharmacol Bull; 1992; 28(2):163-8. PubMed ID: 1513919
[TBL] [Abstract][Full Text] [Related]
18. The effect of urine pH on debrisoquine phenotyping: application of an HPLC-method.
Kallio J
Int J Clin Pharmacol Ther Toxicol; 1990 May; 28(5):223-6. PubMed ID: 2163994
[TBL] [Abstract][Full Text] [Related]
19. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
Wanwimolruk S; Patamasucon P; Lee EJ
Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
[TBL] [Abstract][Full Text] [Related]
20. Polymorphic ochratoxin A hydroxylation in rat strains phenotyped as poor and extensive metabolizers of debrisoquine.
Castegnaro M; Bartsch H; Bereziat JC; Arvela P; Michelon J; Broussolle L
Xenobiotica; 1989 Feb; 19(2):225-30. PubMed ID: 2786290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
